MPO and breast carcinoma: Elevated circulating levels of MPO were found in breast cancer patients that experienced cardiotoxicity, so MPO is now considered a promising biomarker for the early detection of anthracycline-related and anthracycline–trastuzumab cardiac dysfunction, based on the results of several studies [125,126].